Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Illumina, Inc. (ILMN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
409.15-2.43 (-0.59%)
At close: 4:00PM EDT
406.41 -2.74 (-0.67%)
After hours: 05:38PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close411.58
Open411.00
Bid404.00 x 800
Ask409.15 x 1100
Day's Range403.49 - 413.39
52 Week Range288.01 - 555.77
Volume544,841
Avg. Volume788,470
Market Cap64.032B
Beta (5Y Monthly)0.95
PE Ratio (TTM)78.35
EPS (TTM)5.22
Earnings DateNov 04, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est453.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
29% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for ILMN

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Illumina, Inc.
    Analyst Report: Illumina, Inc.Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates revenue from sequencing tools and dedicated consumables (76% of 2020 sales). Illumina’s high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. Services account for 16% of sales and include basic maintenance services, clinical lab applications (such as noninvasive prenatal, oncology, and rare-disease screening), and whole genome sequencing.
    Rating
    Fair Value
    Economic Moat
    26 days agoMorningstar
View more
Advertisement
Advertisement